摘要
目的:探讨缬沙坦对原发性高血压(EH)并心房颤动(Af)患者血清基质金属蛋白酶-2(MMP-2)与组织金属蛋白酶抑制因子-2(TIMP-2)水平的影响。方法:采用定量酶联免疫吸附试验(ELISA)测定28例EH并Af患者(EH并Af组)与30例正常人(正常对照组)血清MMP-2、TIMP-2水平。结果:EH并Af患者MMP-2明显高于正常对照组[(389.58±117.16)∶(291.80±104.15)μg/L,P<0.01],而TIMP-2较正常对照组低[(61.94±27.09)∶(115.22±45.00)μg/L,P<0.01]。EH并Af患者应用缬沙坦治疗6个月后,血清MMP-2水平明显降低(P<0.001),而血清TIMP-2升高(P<0.05)。结论:缬沙坦可降低EH并Af患者血清MMP-2水平,升高TIMP-2水平升高。
Objective：To observe the effects of valsartan on serum matrix metalloproteinase-2（MMP-2） and tissue inhibitor of matrix metalloproteinase-2（TIMP-2） in patients with essential hypertension（EH） and atrial fibrillation（Af）.Method：The plasma levels of MMP-2 and TIMP-2 were measured by ELISA in 30 normal individuals（control group） and 28 patients with EH and Af（EH and Af group）.28 patients with EH and Af before and after 6 months treatment,the plasma levels of MMP-2 and TIMP-2 were measured by ELISA.Result：The level of serum MMP-2 in EH and Af group was significantly higher than that in control group（[389.58±117.16]ng/ml vs [291.80±104.15]ng/ml,P0.01）.The level of serum TIMP-2 in EH and Af group was less than that in control group（[61.94±27.09]ng/ml vs [115.22±45.00]ng/ml,P0.01）.After six months treatment ofvalsartan in patients with EH and Af,serum MMP2 levels tends to fell（268.73±61.56）ng/ml（P0.01）,serum TIMP-2 levels increase to（85.72±43.25）ng/ml（P0.05）.Conclusion：There are higher level of serum MMP-2 and lower serum TIMP-2 in EH and Af patients that those in control group.Valsartan can decrease serum MMP-2 levels and increase serum TIMP-2 levels in patients with EH and Af.
出处
《临床心血管病杂志》
CAS
CSCD
北大核心
2011年第3期171-174,共4页
Journal of Clinical Cardiology
